Hospital Posadas to collaborate with Argentine startup using AI for cancer biomarker detection

The Hospital Posadas in Argentina is set to partner with Kuvia, a local startup leveraging artificial intelligence (AI) to revolutionize cancer biomarker detection. This collaboration marks a significant step in integrating advanced AI technologies into the nation's healthcare system.

“

Our mission is to harness the power of AI to transform cancer diagnosis, making biomarker detection faster and more accessible, with the goal of improving patient outcomes.

Kuvia, founded by bioengineers Ana Gorodisch and Martina Belluomini, aims to transform cancer diagnosis by making biomarker detection faster and more accessible. Their AI system analyzes digitized tissue images, identifying crucial biomarkers in just five minutes. This rapid process contrasts sharply with current methods, which are often slow, expensive, and require specialized infrastructure, limiting accessibility, particularly in resource-scarce regions.

“

The current analysis methods are slow, costly, and out of reach for many clinics because they require specialized infrastructure. This limits their accessibility, especially in regions with fewer resources or underserved areas.

The startup is currently developing a tool with the Garrahan Hospital to detect the BRAF V600E mutation in pediatric cancers. Their AI solution is initially focused on patients with colon and endometrial cancer, with plans to expand to other cancer types. Gorodisch highlighted that the AI-guided treatments are more precise, faster, cheaper, and equally accurate compared to existing methods, contributing to the "democratization" of precision medicine.

“

From our AI, more precise treatments can be guided that complement what is used today. A cheaper, faster, and equally accurate method.

Hospital Posadas views this initiative as providing valuable new tools for its medical team, promising reduced delays and improved patient outcomes. However, Kuvia's system must still gain approval from Argentina's National Administration of Medicines, Food, and Medical Technology (Anmat) before it can be legally implemented across the country.

“

We appreciate this initiative that offers new tools to our medical team and directly impacts the health of our patients with fewer delays and better results.